Latigo Biotherapeutics
PublicLatigo Biotherapeutics is now publicly traded
The data on this page reflects Latigo Biotherapeutics's private-market history up to the point it went public, including its funding rounds, valuation, and investors.
Last Round
Series B
Mar 17, 2025
Total Funding Raised
$285M
Company Overview
Latigo Biotherapeutics operates in Biotech and is based in Thousand Oaks, California. It has raised $285M.
Latigo Biotherapeutics is a biotechnology company developing innovative non-opioid pain medicines that target pain at its source to provide effective, rapid-acting relief without the risk of addiction.
Sector
Biotech
Verticals
Life Sciences
AI Layer
Application
Latigo Biotherapeutics Comparables
Compare Latigo Biotherapeutics with similar companies based on industry and business-model similarity.
| Company | Similarity | Market Cap |
|---|---|---|
| Centrexion Therapeutics | 87% | |
| Tafalgie Therapeutics | 86% | |
| South Rampart Pharma, Inc. | 84% |
For institutional investors. Book with your work email.
Latigo Biotherapeutics Funding Rounds
Historical fundraising activity
| Round | Date | Amount Raised | Valuation | Investors | Sources |
|---|---|---|---|---|---|
| Series B | Mar 17, 2025 | ||||
| Series A | Feb 14, 2024 |
For institutional investors. Book with your work email.
Latigo Biotherapeutics Investors
Notable investors and investment history
| Investor | Rounds |
|---|---|
| Westlake Village BioPartners | Series B, Series A |
| Cormorant Asset Management | Series B |
| Corner Ventures | Series A |
| Blue Owl Capital | Series B |
| Deep Track Capital | Series B |
| 5AM Ventures | Series B, Series A |
| Foresite Capital | Series B, Series A |
For institutional investors. Book with your work email.
Latigo Biotherapeutics Filings
Explore SEC and related filing metadata, where available.
| Type | Date | Amount Offered | Amount Sold | Filing | Pages | Download |
|---|
Filing documents are not displayed on this public page. Request access to learn about available coverage.
Book a demoFor institutional investors. Book with your work email.